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Background: Healthcare workers (HCWs) have been disproportionately affected by
coronavirus disease 2019 (COVID-19), which may be driven, in part, by nosocomial expo-
sure. If HCW exposure is predominantly nosocomial, HCWs in paediatric facilities, where
few patients are admitted with COVID-19, may lack antibodies to severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) and be at increased risk during the current
resurgence.
Aim: To compare the seroprevalence of SARS-CoV-2 amongst HCWs in paediatric facilities
in seven European countries and South Africa (N¼8).
Methods: All categories of paediatric HCWs were invited to participate in the study,
irrespective of previous symptoms. A single blood sample was taken and data about pre-
vious symptoms were documented. Serum was shipped to a central laboratory in London
where SARS-CoV-2 immunoglobulin G was measured.mond Street Institute of
Guilford Street, London
Goldblatt).
y Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article
ivecommons.org/licenses/by-nc-nd/4.0/).
D. Goldblatt et al. / Journal of Hospital Infection 110 (2021) 60e66 61Findings: In total, 4114 HCWs were recruited between 1st May and mid-July 2020. The
range of seroprevalence was 0e16.93%. The highest seroprevalence was found in London
(16.93%), followed by Cape Town, South Africa (10.36%). There were no positive HCWs in
the Austrian, Estonian and Latvian cohorts; 2/300 [0.66%, 95% confidence interval (CI) 0.18
e2.4] HCWs tested positive in Lithuania; 1/124 (0.81%, 95% CI 0.14e4.3) HCWs tested
positive in Romania; and 1/76 (1.3%, 95% CI 0.23e7.0) HCWs tested positive in Greece.
Conclusion: Overall seroprevalence amongst paediatric HCWs is similar to their national
populations and linked to the national COVID-19 burden. Staff working in paediatric
facilities in low-burden countries have very low seroprevalence rates and thus are likely to
be susceptible to COVID-19. Their susceptibility to infection may affect their ability to
provide care in the face of increasing cases of COVID-19, and this highlights the need for
appropriate preventative strategies in paediatric healthcare settings.
ª 2021 The Author(s). Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) was first recognized in December 2019 and rapidly
spread worldwide, with the World Health Organization (WHO)
declaring a pandemic situation on 11th March 2020. Soon after
the identification and genetic sequencing of the virus, diag-
nostic tests became available for the detection of live virus in
human secretions, followed rapidly by tests designed to
measure serum antibodies to SARS-CoV-2 antigens. Antibodies
to SARS-CoV-2 are known to start increasing within 5 days of
exposure [1], and immunoglobulin G (IgG) can be detected in
the serum for many months following exposure. Sero-
epidemiology, the presence of antibody in a representative
community sample, can shed light on overall population
exposure and, when correlates of protection are better
understood, may help to predict both individual and com-
munity susceptibility to infection.
Healthcare workers (HCWs) have had to work throughout
the pandemic and the incidence of coronavirus disease 2019
(COVID-19) among HCWs has been shown, in some studies, to be
higher than in the general population [2,3]. Recently, WHO has
indicated that while HCWs represent <3% of the population in
the large majority of countries and <2% in almost all low- and
middle-income countries, approximately 14% of cases of
COVID-19 reported to WHO are among HCWs. In some coun-
tries, the proportion is as high as 35% (https://www.who.int/
news-room/detail/17-09-2020-keep-health-workers-safe-to-
keep-patients-safe-who).
Seroprevalence has been measured in HCWs to help under-
stand the transmission potential of SARS-CoV-2 in the context
of nosocomial exposure, and also for insight into the true
burden of underlying COVID-19 infection. In many settings, it
has been shown to be significantly higher in HCWs than in the
relevant general population [4e7]. As relatively few children
globally have been admitted to hospital with COVID-19 [8],
staff working in paediatric facilities have been unlikely to face
a significant risk of exposure from their patients [9]. Only two
studies of seroprevalence in paediatric HCWs have been pub-
lished to date. In Barcelona, Spain, seroprevalence of 4% was
discovered in HCWs [10], similar to the rate in a population-
based random sample from the general population in Barce-
lona (5.4%) analysed at approximately the same time (March/
April 2020). In Argentina, the seroprevalence rate inpaediatricians from a single children’s hospital 3 months into
the pandemic was 0.9% [11]. While SARS-CoV-2 has been
studied intensely in high-prevalence countries that bore the
brunt of the initial pandemic, nothing is known about paedi-
atric HCW serostatus in other countries. Understanding levels
of seroprevalence in such staff could provide insight into the
general prevalence of SARS-CoV-2 in cities or countries where
mass testing for the presence of virus in swabs or community-
based sero-surveys have not been widely implemented or are
suboptimal, and thereby uncover rates of asymptomatic
infection that have led to seroconversion. Additionally, such
information can help healthcare facilities plan for the current
surge in SARS-CoV-2 infection and, where relevant, target
vaccine delivery.
There is currently little standardization of assays designed
to measure antibodies to SARS-CoV-2, resulting in assays of
varying sensitivity and specificity being used [12] and con-
sequent difficulty in the comparison of seroprevalence rates
between studies and/or countries. As such, this study was
designed to compare rates of SARS-CoV-2 antibody positivity in
HCWs working in paediatric facilities in seven different Euro-
pean countries and South Africa. By centralizing all of the
testing in a single laboratory in London, UK, methodological
laboratory issues that may influence comparisons were elimi-
nated. In order to contextualize potential differences in sero-
prevalence rates between the countries participating in this
study, publicly available data were accessed regarding the
dates of the initial cases and subsequent epidemiology of
COVID-19 in each participating country, the mobility of citizens
in each country relative to national restrictions on movement,
and government responses during the pandemic.Methods
This study was undertaken in HCWs in paediatric facilities in
seven European sites and one South African site. The study was
initiated at Great Ormond Street Hospital, London where local
hospital staff were invited to enrol in a prospective longitudinal
cohort study of SARS-CoV-2 serology (COSTARS, IRAS 282713,
ClinicalTrials.gov Identifier: NCT04380896). Collaborators
based in paediatric healthcare facilities were invited to join a
multi-centre study with a similar design. Ethical approval was
obtained locally by the lead investigators at each site. A











































































































































































































































































































































































































































































































































































































































































































































































































D. Goldblatt et al. / Journal of Hospital Infection 110 (2021) 60e6662study and governed the transfer of data and serum was signed
between each centre and the principal investigator’s labo-
ratory at Great Ormond Street Institute of Child Health, Uni-
versity College London.
Staff of all categories in each healthcare setting were invi-
ted to join the study, irrespective of symptoms or whether they
suspected they had previously had COVID-19. The number of
staff recruited was a convenience sample matched to the
capacity for laboratory testing. Staff who consented to join the
study provided a single 2-mL blood sample and completed a
questionnaire focused on documenting the symptoms of COVID-
19 since the onset of the pandemic, prior known exposure, and
the outcome if a viral swab for SARS-CoV-2 RNA polymerase
chain reaction (PCR) had been obtained.
Serology
Serum was prepared and aliquoted, given a unique identifier
locally, and stored frozen until batch shipping to the WHO
International Reference Laboratory for Pneumococcal Serology
at University College London, where samples were analysed for
the presence of IgG to SARS-CoV-2 nucleocapsid protein (Epit-
ope Diagnostics Inc, San Diego, CA, USA), as described pre-
viously [13]. All positive or equivocal samples were re-assayed
in a multiplexed assay measuring IgG to SARS-CoV-2 nucleo-
capsid protein, receptor binding domain of S1 and trimeric
spike antigen (MSD SARS-Coronavirus Plate 1, Rockville, MD,
USA) to confirm positivity, and to establish whether equivocal
samples were positive or negative. The MSD assay has under-
gone extensive evaluation in the London laboratory [14].
Data sources
National case counts at the time of sampling were taken
from data collated from WHO, US Centers for Disease Control
and Prevention, and other sources, and available on the public
website bing.com (https://www.bing.com/covid). Numbers of
cases were converted to rates of COVID-19 per 100,000 pop-
ulation using population estimates published by Eurostat
(https://ec.europa.eu/eurostat/data/database). Mobility
data for each individual country in the period between the
onset of the first case and cohort recruitment were taken from
publicly available Google Mobility data available at https://
www.google.com/COVID-19/mobility/. Government respon-
ses to the pandemic were accessed at the publicly available
website hosted by the Blavatnik School of Government at the
University of Oxford (https://www.bsg.ox.ac.uk/research/
research-projects/coronavirus-government-response-
tracker). The Oxford COVID-19 Government Response Tracker
systematically collects information on several different com-
mon policy responses that governments have taken to respond




In total, 4114 HCWs were recruited between 1st May and
mid-July 2020 from the nine sites, although the cohort size










0 5 10 15
Seroprevalence (%)
20 25 30
Figure 1. Seroprevalence estimates for severe acute respiratory syndrome coronavirus-2 antinucleocapsid immunoglobulin G in
healthcare worker cohorts in eight countries.
D. Goldblatt et al. / Journal of Hospital Infection 110 (2021) 60e66 63Latvia, Lithuania and Romania, >90% of the staff included in
the study were female, and females dominated all of the
cohorts reflecting the gender make-up of staff in the paediatric
health setting. The mean age of participants in each cohort was
similar and ranged from 38 to 50 years, although cohorts had a
wide age range (19e78 years). The time taken to recruit the
entire cohort varied between sites. Some sites recruited staff
over days, while others continued recruitment over months.
The proportion of HCWs in each cohort reporting symptoms
compatible with COVID-19 prior to recruitment variedTable II
Google Mobility and the Oxford COVID-19 Government Response
Tracker for the eight participating countries















UK -33 75significantly: <1% (Greece and Romania), 9e18% (Austria,
Estonia and Lithuania), 22% (Latvia) and 30e45% (South Africa
and UK).
The majority of cohort recruitment took place between May
and June 2020 with the exception of Greece, where recruit-
ment started in mid-June and extended into July 2020; Austria,
where recruitment was only undertaken in July 2020; and South
Africa, where recruitment extended from mid-June until mid-
August 2020 which coincided with the peak of the pandemic
(https://www.nicd.ac.za/diseases-a-z-index/covid-19/
surveillance-reports/). London recruited throughout May and
June 2020, and the two periods were separated out for ana-
lytical purposes.
Despite 16e22% of staff in Austria, Estonia and Latvia
reporting symptoms prior to study recruitment, none had a
positive viral swab for SARS-CoV-2 RNA recorded. In Austria, all
staff participating in the study were swabbed regularly (two
weekly) as part of local health measures. The proportion of the
cohort with a positive PCR result in Lithuania, Romania and the
UK was <1%, and all those with positive PCR results were also
antibody-positive. The positive PCR rate in South Africa was
higher at 7.66%.Serology
Seroprevalence rates for three of the four countries with no
positive PCR results were zero, although one of 76 workers was
IgG-positive in Greece (Figure 1). Similarly low seroprevalence
D. Goldblatt et al. / Journal of Hospital Infection 110 (2021) 60e6664rates were found in Romania [one of 224 HCWs tested IgG-
positive (0.8%)] and Lithuania [two of 300 HCWs tested IgG-
positive (0.66%)]. Seroprevalence in Cape Town HCWs was
10.4%, and 15.4% and 16.93% of the London cohort were IgG-
positive for the May and June cohorts, respectively. When
comparing seroprevalence rates for the individual cohorts with
the rates of COVID-19 cases/100,000 population in each coun-
try at the time of sampling, some anomalies were noted
(Table I). For those countries with <100 cases per 100,000
population (Greece, Latvia, Lithuania and Romania), seropre-
valence rates were low (0e1.3%). However, Estonia and Aus-
tria, with rates of 148.23 and 225.76/100,000 population,
respectively, had no seropositive HCWs in their cohorts despite
17% of their cohorts reporting symptoms compatible with
COVID-19 (although no PCR-positive results). The UK and South
Africa had high rates of COVID-19 at the time of recruitment,
and this was reflected in high seroprevalence rates.
The time reported between symptoms compatible with
COVID-19 and blood sampling was similar for those cohorts with
significant numbers of symptomatic staff. The number of days
ranged from 89 (UK, June cohort) to 116 days (Austria), and this
is unlikely to be responsible for the differences noted between
countries. South Africa had the shortest mean time between
symptoms and blood sampling (46 days), yet had a seropreva-
lence rate lower than the UK. Furthermore, the two UK cohorts
had different times between symptoms and sampling (64 days
for the May cohort and 89 days for the June cohort), but
seroprevalence rates were higher for the cohort with a longer
gap, suggesting that waning antibody is unlikely to be relevant
over a period of 60e90 days.Mobility and government response
Google Mobility data, looking at changes in non-residential
activities including visits to retail outlets, parks, driving and
use of public transport for the relevant areas of each country in
this analysis, revealed some differences between the countries
but none appeared to correlate with seroprevalence (Table II).
The smallest change for the eight countries was Estonia with a
-11% change, followed by Latvia and Lithuania with -19 and
-21% change, respectively; however, these three countries had
seroprevalence rates <1%. For the other six countries, there
was a greater reduction in mobility during the initial phases of
the pandemic, with changes ranging from -31% (Austria) to -42%
(Romania). The countries with the highest seroprevalence
rates showed changes in mobility of -40% (South Africa) and
-33% (UK).
The Oxford COVID-19 Government Response Tracker score
was compared for each country at 100 days following the first
case, which was approximately the first or second week of June
2020 for the eight countries in this study (Table II). For the
countries with low seroprevalence rates (and generally lower
case rates), the scores ranged from 50% to 70%. The country
with the highest score was South Africa (90%), which reflects
the severe lockdown imposed early on in the pandemic.
Despite the high score, the seroprevalence rate in the South
African cohort was the second highest in this study, suggesting
that the score may accurately reflect national responses to the
pandemic, but the response does not necessarily predict the
spread of SARS-CoV-2 in a population.Discussion
HCWs have continued to work during the pandemic to
maintain health services, and have therefore been at increased
risk of exposure to SARS-CoV-2. As COVID-19 may be asympto-
matic, additional methods are required to estimate the true
burden of disease and, by implication, the number of staff that
might be protected as a result of recovering from infection.
Detection of virus in throat/nasal swabs and serological tests of
specific antibody have both been used in studies of clinical
facing front-line HCWs to try and quantify the burden of dis-
ease in this group. However, estimates of seroprevalence
amongst HCWs have varied widely; for example, within Europe,
Germany [15], Greece [16], Croatia [17] and Austria [18] have
demonstrated low seroprevalence rates for HCWs (1%, 1.07%,
2% and 3.2%, respectively), while Belgium (6.4%) [19], Spain
(9.3%) [6] and the UK [4,20] have had higher rates in some
studies. However, interpretation of differences in seropreva-
lence rates between countries is complicated by the fact that
rates have been shown to vary widely between studies in the
same country. For example, five independent studies con-
ducted within hospitals that are part of the UK National Health
Service have reported seroprevalence estimates ranging from
10.6% [21] or 10.7% [22] at study entry to an overall rate of
24.4% [4] or 31.64% [7], or, in one study, 25% at entry with a
subsequent overall rate of 45% [20]. In the USA, in a con-
venience sample of front-line HCWs who worked with patients
with COVID-19 at 13 geographically diverse US academic med-
ical centres, seroprevalence rates were found to range by
hospital from 0.8% to 31.2% (median 3.6%). Higher rates were
found in those hospitals situated in areas with high community
cumulative incidence of COVID-19 [5].
Apart from differences between countries or hospitals,
other factors have also been shown to influence seropositivity
rates, including gender [5], ethnicity [4,5] and category of
hospital work (e.g. housekeepers higher than intensive care
unit staff) [4]. In contrast, in Belgium, a study found no rela-
tionship between direct clinical care of patients with COVID-19
and seroprevalence rates, but instead found that rates corre-
lated with reported household contacts [23].
Comparison of seroprevalence rates between studies is
complicated by the varying performance of assays used to
measure SARS-CoV-2 serum responses. There is currently no
standardization of assays and, as shown within the same
seroprevalence study, the performance of seven different
assays may differ widely [19].
To reliably undertake transnational comparison, this study
centralized testing in a single laboratory. Staff in all partic-
ipating centres were recruited irrespective of a history of
clinical symptoms that could be construed as COVID-19, and
thus should be considered as an unbiased sample of HCWs. All
worked in paediatric facilities, although some were embedded
in larger adult facilities. No attempt was made to stratify
between clinical facing and non-clinical staff, as HCWs in
paediatric facilities are generally not in high-risk environments
as children represent only a small number (6%) of total COVID-
19 admissions [24], and young children may be less likely to
transmit virus than older individuals [25]. All cohorts in this
study were dominated by females, so gender differences in
seroprevalence rates should not account for the differences
noted in the cohorts, and the mean ages and age ranges
D. Goldblatt et al. / Journal of Hospital Infection 110 (2021) 60e66 65overlapped significantly and were thus comparable. The
recruitment period (both time taken in days, and months in
which recruitment took place) differed between the cohorts,
although the majority of recruitment took place between May
and July 2020 either during or after the initial peak of disease in
most countries. The UK site enrolled two cohorts, one in May
and one in June 2020 e both periods were associated with
similar numbers of new cases in London, and relatively small
differences in seroprevalence rates were seen between the
two cohorts. This suggests that month of sampling is unlikely to
have had a major effect on the results of this study as most of
the sampling in the eight participating centres occurred at a
similar time in relation to the peak of disease. The time
between symptom onset and blood testing was comparable for
most cohorts, with the shortest mean time being 46 days (South
African cohort). As most assays detect antibody reliably at
least 15 days after exposure [26], most positive cases would
have been captured in the study cohorts, although it is unclear
if some staff may have lost IgG and thus sero-reverted. If this
were the case, it would have affected the seven cohorts with
longer time periods between symptom onset and testing
equally. As in other studies [23], there was discrepancy
between the proportion of staff reporting symptoms compat-
ible with COVID-19 and the seroprevalence rate. This was most
pronounced for the UK cohort in June 2020 where 76.6% of the
cohort reported compatible symptoms yet seroprevalence was
‘only’ 16.93%.
Interestingly, the seroprevalence rates for several of the
HCW cohorts were similar to population-based estimates for
the same city or region. Seroprevalence for the London cohort
of HCWs (15.4e17%) was very similar to that measured for
London-based blood donors analysed by Public Health England
in May and June 2020 (15e16%) [27]. Seroprevalence for the
Greek HCW cohort was 1.3% (based on a single case), which was
similar to that found in a community-based study of seropre-
valence in residual sera in Athens (0.93%) [28]. The absence of
any IgG-positive HCWs in Austria similarly reflects the very low
national seroprevalence rate of 0.15% (http://www.statistik.
at/web_en/statistics/PeopleSociety/health/123052.html).
The absence of any IgG-positive HCWs in the Estonian cohort
reflects the very low seroprevalence rate in Tartu (1.6%) [29],
and the low seroprevalence rate in the Lithuanian cohort
(0.66%) was below the rate of 1.31% seen in a population-based
survey in Vilnius (https://sam.lrv.lt/lt/naujienos/pristatyti-
pirminiai-populiacijos-tyrimo-rezultatai). Similarly, blood
donor testing in Latvia revealed a seroprevalence rate of 0.4%
(personal communication). The authors found one study of
paediatric HCWs conducted in Spain, where the seroprevalence
rate among the HCWs was similar to that in the general pop-
ulation [10], and one study of physicians in a children’s hospital
in Argentina with a seroprevalence rate of 0.9% [11]. Together,
these data suggest that HCWs in paediatric settings are nomore
likely than the general population to be seropositive for SARS-
CoV-2, and household contacts may be an important source of
infection [23].
This study has a number of limitations. The cohort sizes
differed significantly between centres, although all but one
centre enrolled >120 subjects. No attempt was made to adjust
for sensitivity of the EDI assay, as this study was comparative
and the key outcome was comparison of rates between the
participating countries. The true seropositive rate might be
slightly higher as assay sensitivity was assessed as 92.4% withpublished sensitivity as low as 80% [30]. However, all equivocal
samples that were borderline in the EDI assay were re-assayed
in the MSD assay which has very high sensitivity [14], increasing
the overall sensitivity for detecting positive cases in these
cohorts. As the cohorts separated into six countries with rela-
tively low seropositivity rates and two countries with relatively
high seropositivity rates, this limited the opportunity to cor-
relate findings with factors measured by Google Mobility data
or the response of individual governments to the pandemic.
In conclusion, this study shows that HCWs in paediatric
facilities have seroprevalence rates that are similar to their
local general population, which are closely related to the
overall burden of COVID-19 in the areas where the hospitals are
based. While this may be interpreted as the success of personal
protection in paediatric healthcare facilities, it is more likely
to be the absence of nosocomial exposure or lack of trans-
mission from infected children to adults, and thus a risk of
exposure to SARS-CoV-2 that is similar to that of the general
public. The relatively small proportions of HCWs with anti-
bodies in six of the eight participating centres suggest that, as
the current second wave of infections increases, staff working
in paediatric facilities remain susceptible to infection. A recent
outbreak amongst staff in a paediatric intensive care unit in
Germany illustrates the serious consequences of infection for
health services [31]. Measures to monitor and protect paedi-
atric staff both at work and at home should be instituted and
adhered to in order to avoid shortages of critical staff in the
health service, and seronegative staff should be targeted for
vaccination where available.
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